Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 6/20 | 0.47 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TPSAB1 | Q15661 | 4/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2933075 | 0.90 | PTPN1 (0.45) | PTPN1PRMT1PTPN2ALDH1A1POLB | |
| SCHEMBL3202520 | 0.90 | PTPN1 (0.48) | PTPN1PTPN2ALDH1A1TPSAB1POLB | |
| SCHEMBL2929970 | 0.88 | PTPN1 (0.47) | PTPN1PRMT1PTPN2 | |
| SCHEMBL3216109 | 0.87 | PTPN1 (0.47) | PTPN1PTPN2ALDH1A1TPSAB1POLB | |
| SCHEMBL2934340 | 0.86 | PTPN1 (0.47) | PTPN1PTPN2ALDH1A1KMT2ATDP1 | |
| SCHEMBL4557753 | 0.85 | PTPN1 (0.44) | PTPN1PTPN2ALDH1A1TPSAB1POLB | |
| SCHEMBL2937152 | 0.84 | PTPN1 (0.49) | PTPN1PTPN2ALDH1A1MAPK1KMT2A | |
| SCHEMBL3228192 | 0.83 | PTPN1 (0.42) | PTPN1ALDH1A1MAPK1 | |
| SCHEMBL3213361 | 0.83 | PTPN1 (0.46) | PTPN1ALDH1A1MAPK1KMT2APOLB | |
| SCHEMBL3200992 | 0.82 | PTPN1 (0.45) | PTPN1PTPN2ALDH1A1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084448-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | claimed |
| US-20090181928-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | claimed |
| EP-2038267-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | Novartis AG (CH) | 2009-03-25 | — | — | EP | claimed |
| WO-2007115058-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | claimed |
| US-8084448-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-20100305036-A1 | COMBINATION OF PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND HUMAN GROWTH HORMONE FOR THE TREATMENT OF MUSCLE ATROPHY AND RELATED DISORDERS | NOVARTIS AG (SZ) | 2010-12-02 | — | — | US | disclosed |
| US-20100035860-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE FOR THE PROMOTION OF PHYSIOLOGICAL CARDIAC HYPERTROPHY | JEYASEELAN JEY RAJU | 2010-02-11 | — | — | US | disclosed |
| US-20090181928-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181928-A1 | ORGANIC COMPOUNDS | PTPRS, PTPRO, PTPRC | PTPN1 21/4885PRMT1 2126/4885CYP19A1 1354/4885 |
| US-20100305036-A1 | COMBINATION OF PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND HUMAN GROWTH HORMONE FOR THE TREATMENT OF MUSCLE ATROPHY AND RELATED DISORDERS | MUSK, PPP5C, PPP3CA | PTPN1 35/4885PRMT1 1107/4885CYP19A1 945/4885 |
| US-20100035860-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE FOR THE PROMOTION OF PHYSIOLOGICAL CARDIAC HYPERTROPHY | PPM1A, TNNI3, PTPA | PTPN1 41/4885PRMT1 806/4885CYP19A1 4256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.